Nonviral Gene Therapy Platform Delivers CRISPR/Cas9 to Tumors

January 24, 2018

(Genetic Engineering & Biotechnology News) – A platform for gene delivery and tumor therapy has been introduced that harnesses the power of the CRISPR/Cas9 gene-editing system. At the same time, the platform avoids some of the drawbacks of the CRISPR/Cas9 system. Specifically, the platform can cope with CRISPR/Cas9’s sheer bulk, achieving highly efficient and targeted delivery to tumor cells. At the same time, it provides a multifunctional bonus: the new system incorporates gold nanoparticles that can serve as thermotherapeutic agents.

Recommended Reading